NeoPlasMarker® (NPM®) assay is an innovative platform to assess dynamic status of patients with cancer disease. Highly cancer-specific gene signatures are clinically validated with tumor tissues, liquid biopsies, and pleural effusions. Analytical services have been providing for clinical organizations.

1. NPM® assay for assessment of clinical outcome of cancer patients
   • Provide precise and personal information of status of patients, such as therapeutic response, early detection of distant metastasis, and recurrence.
   • Advantages: low invasive and multiple samplings of peripheral blood for analysis
   • High performance quality : sensitivity, specificity, and accuracy 80~85%;
   • NPM® panels for clinical service items:
     NPM®-CR assay: colorectal cancer
     NPM®-LC assay: non-small cell lung cancer
2. NPM®-mPE assay for detection of malignant pleural effusion (MPE)
   Provide the information of cancer-associated gene signature of cells, which are cytologically or pathologically negative (unmet need).

These assays allow early detection of metastatic cancer cells and physicians could arrange proper treatment to prolong the survival time of patients. Cooperation, license, or Joint Venture is welcomed.